Clopra and Miglitol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Clopra (metoclopramide hydrochloride) and Miglitol (miglitol). Common drug interactions include in-stent coronary artery restenosis among females and hypoglycaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Clopra and Miglitol. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Clopra?

Clopra has active ingredients of metoclopramide hydrochloride. eHealthMe is studying from 81,430 Clopra users. Check the latest studies of Clopra.

What is Miglitol?

Miglitol has active ingredients of miglitol. eHealthMe is studying from 1,515 Miglitol users. Check the latest studies of Miglitol.

On Jul, 28, 2026

21 people who take Clopra and Miglitol together, and have interactions are studied.

What are the common drug interactions of Clopra and Miglitol, by gender? *:

female:

In-stent coronary artery restenosis
Hepatocellular injury (liver injury)
Coronary artery restenosis (recurrence of narrowing of artery)
Device occlusion
Injection site haemorrhage (bleeding from injection site)
Liver disorder (liver diseases)

male:

Hypoglycaemia (deficiency of glucose in the bloodstream)
Thrombocytopenia (decrease of platelets in blood)
Decreased appetite
Gastric ulcer (stomach ulcer)
General physical health deterioration (weak health status)
Nausea (feeling of having an urge to vomit)
Plasma cell myeloma (cancer that begins in plasma cells)
Urinary retention (the inability to completely or partially empty the bladder)
Troponin t increased
Pneumonia

What are the common drug interactions of Clopra and Miglitol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Thrombocytopenia (decrease of platelets in blood)
Troponin t increased
Pneumonia
Pulmonary embolism (blockage of the main artery of the lung)
Injection site haemorrhage (bleeding from injection site)

60+:

In-stent coronary artery restenosis
Coronary artery restenosis (recurrence of narrowing of artery)
Device occlusion
Gastric ulcer (stomach ulcer)
General physical health deterioration (weak health status)
Liver disorder (liver diseases)
Nausea (feeling of having an urge to vomit)
Plasma cell myeloma (cancer that begins in plasma cells)
Urinary retention (the inability to completely or partially empty the bladder)
Hepatocellular injury (liver injury)

What are the existing conditions these people have? *

High Blood Pressure: 13 people, 61.90%
Diabetes: 13 people, 61.90%
Stable Angina (a constant chest pain): 11 people, 52.38%
Percutaneous Coronary Intervention: 11 people, 52.38%
High Blood Cholesterol: 11 people, 52.38%
Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 3 people, 14.29%
Nausea And Vomiting: 2 people, 9.52%
Nausea (feeling of having an urge to vomit): 2 people, 9.52%
Multiple Myeloma (cancer of the plasma cells): 2 people, 9.52%
Irritability: 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Clopra and Miglitol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously